date:May 07, 2012
pid profile and insulin sensitivity and an attenuation of estimated [coronary heart disease] risk, highlighting the additional benefit of flavonoids to standard drug therapy in managing [cardiovascular disease] risk in patients with type 2 diabetes,wrote the researchers inDiabetes Care.
Our study is the only combined flavonoid trial and the longest flavan-3-ol intervention to date, and our findings have potential clinical relevance.
The study used Barry Callebauts Acticoa product and Frutaro